Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03093753
Other study ID # MEEC 15-044
Secondary ID
Status Completed
Phase N/A
First received March 22, 2017
Last updated April 17, 2018
Start date July 2016
Est. completion date September 2017

Study information

Verified date April 2018
Source University of Leeds
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Consumption of carbohydrate containing foods or sugary drinks brings about changes to the blood glucose levels. After a meal or drink, blood glucose rises until it reaches a peak concentration usually after 30 minutes. When the body senses the increase in blood glucose, a hormonal process involving insulin takes place to ensure that the glucose is taken up from the blood for storage and where it is needed for energy in the body. This process then brings about a decrease in the concentration of glucose until it reaches approximately the starting concentration. The original concentration of glucose is attained approximately 2 hours after eating or drinking a carbohydrate food or sugary drink respectively in healthy people.

Different carbohydrates and sugary drinks have different effects on blood glucose response depending on the amount as well as the type of carbohydrate. Those that give rise to a high glucose response compared to a reference carbohydrate (usually glucose) are said to be high glycaemic index (GI) foods and those with a lower glucose response compared to a reference carbohydrate (usually glucose) are said to be low glycaemic index (GI) foods.

Research has shown that diets that give rise to a high glucose response are associated with a number of abnormalities like increased risk of metabolic syndrome. Metabolic syndrome mostly comprises of insulin resistance and glucose intolerance which gives an increased risk of type 2 diabetes. It also gives rise to other conditions like high blood pressure (arterial hypertension), elevated blood insulin levels (hyper-insulinemia), elevated amounts of fat in the liver (fatty hepatosis) and elevated amounts of lipids in the blood (dyslipidemia). After type 2 diabetes become clinically apparent, the risk of cardiovascular disease also rises. Research has also shown that foods/drinks which raise blood glucose levels gradually (low GI) rather than rapidly (high GI) have health benefits which include reducing the risk of metabolic syndrome. Laboratory studies have shown that polyphenols found in fruits, vegetables and plant based foods have a positive effect on carbohydrate metabolism and can lower the blood glucose levels.

This research will determine whether the presence of polyphenols in the diet has any lowering effect on the blood glucose levels and hence the glycaemic index of foods. This will be determined by asking volunteers to consume pomegranate polyphenols together with different carbohydrate sources which will define the 6 different interventions. The blood glucose response of bread will be determined initially as a control reference. All meals will be consumed in random order.

Analysis will be done by measuring blood glucose response after consumption of the control reference meal and the test meal containing polyphenols and then determining the incremental area under the glucose curve.

THE SIX DIFFERENT INTERVENTIONS MAY OR MAY NOT BE COMBINED FOR PURPOSES OF PUBLISHING RESULTS. EACH INTERVENTION WILL AIM TO HAVE AT LEAST 10 PARTICIPANTS.


Description:

The world health organisation has reported that over 220 million people suffer from diabetes worldwide and that by the year 2030, this number will be doubled. The WHO also reports that in 2004, about 3.4 million people died from high blood sugar. About 90% of all diabetes cases is due to type II diabetes. Type 2 diabetes is largely due to overweight and lack of physical activity characterised by high glucose levels (hyperglycaemia).

In the human diet, the source of blood glucose is carbohydrates. Dietary carbohydrate is important to maintain glycaemic homeostasis and provides the most of the energy in the diets of most people. The control of blood glucose is a hormonal process and it is very important to human physiology. Hormonal processes involve the release of insulin from the β- cells of the pancreatic cells which stimulates the uptake of glucose after a meal, to other tissues either for utilisation (glycolysis) or to be stored in the liver as glycogen (glycogenesis). When blood glucose falls below normal, glucagon is secreted from the pancreatic α-cells and it promotes liver glucose production by inducing the generation of glucose from non-carbohydrate substrates such as amino and fatty acids (gluconeogenesis) and the generation of glucose from glycogen (glycogenolysis).

When the glucose homeostasis hormonal control fails, it entails high blood glucose levels (postprandial hyperglycaemia) which can lead to metabolic syndrome which includes obesity, impaired glucose tolerance (IGT), hypertension and dyslipidemia. Disturbance of glucose homeostasis can also lead to other symptoms such as inflammation and oxidative stress at the whole body level as well as disturbances of the functionality in several organs as well as diabetes. Therefore, as much as carbohydrates are required in the human body as a major source of energy, too much in the diet can have adverse health effects especially the one with high glycaemic effect.

The proposed mechanism adapted from Aston, 2006 of how carbohydrates may affect human health is that when there is a continual presence of high glycaemic index foods in the diet, this gives rise to postprandial glucose rise as well as high insulin demand to act on the high blood glucose levels in the blood. Postprandial glucose rise and high insulin demand may lead to insulin resistance which is the major component of metabolic syndrome. High insulin demand may also lead to β-cell failure which may also result in hyperglycaemia which is also a cause of insulin resistance. Insulin resistance and hyperglycaemia are risk factors for metabolic syndrome and diabetes type 2.

Scientific evidence suggest that postprandial hyperglycaemia in humans has a major role to play in health priorities like type 2 diabetes and blood glucose control. It has been reported that about 90% of all diabetes cases consist of type 2 diabetes. Apart from type I and type 2 diabetes, there are other related conditions which include pre-diabetes (impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) as well as metabolic syndrome (obesity, hypertension and insulin resistance). It has been reported that pre-diabetes and metabolic syndrome increases the risk of developing cardiovascular disease and diabetes mellitus. The glycaemic index was originally proposed with the aim of managing diabetes. However, recent studies have shown that the GI has potential in the prevention of type 2 diabetes as well as in the treatment of metabolic syndrome. Research has shown that high GI diets are associated with increased risk of developing type 2 diabetes. More research has shown that high GI diet is associated with a number of abnormalities like increased metabolic syndrome and insulin resistance. In the same way, a low GI diet is said to improve insulin sensitivity but more research is needed to support this. A few studies have shown this to be the case. However it was observed that it was difficult to know whether this was as a result of improved insulin sensitivity, or improved insulin secretion or due to reduced rate of glucose absorption.

Potential solution having anything in the diet that can either slow down the digestion and absorption of carbohydrates can help reduce the risk. Among others, two potential solutions are that of consumption of low glycaemic index foods or having ingredients in the diet that can reduce the glycaemic index of foods as well as postprandial blood glucose levels. The presence of inhibiting components in the diet that can reduce postprandial glucose can also be a solution to reducing the risk. Drugs like acarbose are currently used in some countries for the management of type 2 diabetes which act by inhibiting carbohydrate digestive enzymes. However, the use of acarbose has side effects such as nausea, flatulence and diarrhoea. It has been reported that polyphenols also have the potential to inhibit the rise in blood glucose by hindering the rapid absorption of glucose.

A recent review has reported that research using animal models as well as a limited number of human studies, have shown that polyphenols and polyphenol rich foods or beverages have the potential to affect postprandial glycaemic responses and fasting glycaemia as well as an improvement of acute insulin secretion and sensitivity. Other possible mechanisms as reported in the review include pancreatic β- cells stimulation to secrete insulin as well as activation of insulin receptors, modulation of the release of glucose from the liver as well as of intracellular signalling pathways and gene expression.

Another recent review concluded that it is very possible that the effects of polyphenols in the diet will affect glycaemic index of foods as well as postprandial glucose responses in humans. The two mechanisms highlighted by which this can be achieved being the inhibition of sugar metabolising enzymes as well as transporters. This potential action of polyphenols can thus be compared to that of acarbose which acts by the same mechanism and research in chronic intervention studies has shown that it reduces diabetes risk.

This research will involve the use of soluble olive powder as a source of polyphenols to determine its effects on the glycaemic response when consumed together with a carbohydrate source. Four interventions will be carried out as follows:

1. White bread as source of carbohydrate

2. Whole meal bread as source of carbohydrate

3. Glucose as source of carbohydrate

4. Sucrose as source of carbohydrate

5. White bread as source of carbohydrate but with 3 days high fat diet prior to the study visit.

6. White bread as source of carbohydrate but with 3 days high carbohydrate diet prior to the study visit.

The study was approved by the University of Leeds Mathematical and Physical Sciences (MAPs) ethical committee with application number MEEC15-044. At least 10 volunteers will be recruited for each intervention (white bread, whole bread, glucose, sucrose, 3 days high fat diet, 3 days high carbohydrate diet). The volunteers will be screened for their fasting blood glucose level. They will need to be healthy and their fasting blood glucose levels should fall within the healthy range of 4.3-5.9mmol/L.

The volunteers are scheduled to attend 3 visits. During each visit, the volunteer comes fasted in the morning and the fasting blood glucose is measured by the use of a glucometer. The volunteer is then given a test meal which will be randomized and blood glucose will be measured at 15, 30, 45, 60, 90, 120,150 and 180 minutes after the first bite of the test meal. The results will be used to plot the area under the curve and results obtained after consuming test meals will be compared to those obtained after consumption of control meals.

THE SIX DIFFERENT INTERVENTIONS MAY OR MAY NOT BE COMBINED FOR PURPOSES OF PUBLISHING RESULTS. EACH INTERVENTION WILL AIM TO HAVE AT LEAST 10 PARTICIPANTS.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date September 2017
Est. primary completion date August 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

Measured

- Fasting plasma glucose between 3.9 -5.6 mmol/L Self-assessed

- Apparently healthy

- Not diabetic

- Not pregnant nor lactating

- Not on special diet (for loosing weight)

- Not on long term prescribed medication

Exclusion Criteria:

Measured

- Fasting plasma glucose >5.6 mmol/L

Self-assessed

- Not healthy

- Diabetic

- Pregnant or lactating

- On special diet (for loosing weight)

- On long term prescribed medication

- Smoker

- Diabetic

- Allergic to olives

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control (study 1)
Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
Test (study 1)
The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
Control (study 2)
Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
Dietary Supplement:
Test (study 2)
The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
Other:
Control (study 3)
Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
Dietary Supplement:
Test (study 3)
The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
Other:
Control (study 4)
Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
Dietary Supplement:
Test (study 4)
The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
Other:
Control (study 5)
Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
Test (study 5)
The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
Control (study 6)
Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Test (study 6)
High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Control (study 7)
Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
Test (study 7)
High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Leeds

Outcome

Type Measure Description Time frame Safety issue
Primary Incremental area under the glucose curve 9 months
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Recruiting NCT03775733 - Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia N/A
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Recruiting NCT02885922 - The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
Recruiting NCT02885909 - Inpatient Blood Glucose Control in Taichung Veterans General Hospital Phase 4
Completed NCT02012465 - Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients Early Phase 1
Withdrawn NCT01488383 - Effect of Stevioside in Postpandrial Glucose in Healthy Adults N/A
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01803568 - Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU N/A
Completed NCT01810952 - The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Phase 4
Active, not recruiting NCT01247714 - Clinical Evaluation of a Specific Enteral Diet for Diabetics N/A
Not yet recruiting NCT00846144 - The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients N/A
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Recruiting NCT00654797 - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2 Phase 2
Completed NCT00468494 - Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia? N/A
Completed NCT00394407 - Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes Phase 4